Do acid suppressive drugs (pantoprazole and ranitidine) attenuate the protective effect of alendronate in estrogen-deficient osteoporotic rats?

• DOI: 10.1016/j.ejr.2017.08.003
• Publication Date: 2017-08-20T11:30:39Z
• Authors: Afaf S. Osman; Dina A. Aly Labib; Abeer I. Omar
• Keywords: Pantoprazole; Osteopenia

Alendronate is a drug of choice in the treatment postmenopausal osteoporosis. Acid suppressive drugs are recently used combination with alendronate to protect against stomach ulceration and oesophagitis occurring as serious problems patients under this treatment. To study effect pantoprazole ranitidine on anti-resorptive rat model 64 female Wister albino rats were included (8 rats/group). Treated groups Ovariectomized bilaterally induce Rats treated orally (3 mg/kg/day), (20 combined or for 4 weeks. Bone mineral density (BMD) was determined using dual-energy X-ray absorptiometry scan. Serum bone-specific alkaline phosphatase (BSALP), serum calcium, cortical thickness histopathological examination assessed. Induction osteoporosis significantly elevated BSALP, decreased bone increased score. Ranitidine resulted insignificant changes tested parameters. Pantoprazole given alone, calcium BSALP. At end experiment, improved BSALP level, BMD, This improvement not affected by combining alendronate. Meanwhile, caused significant deterioration proved safer than high risk alendronate-treated patients. Clinicians should carefully judge indication use acid suppressing medications osteoporotic